Copyright
©The Author(s) 2015.
World J Pharmacol. Mar 9, 2015; 4(1): 47-57
Published online Mar 9, 2015. doi: 10.5497/wjp.v4.i1.47
Published online Mar 9, 2015. doi: 10.5497/wjp.v4.i1.47
Name | Histopathologicalclassification | Immunohistochemicalclassification |
MCF-7 | Luminal A | ER+, PR+, Her2- |
SUM185 | Luminal A | ER+, PR-, Her2- |
T47D | Luminal A | ER+, PR+, Her2- |
BT-474 | Luminal B | ER+, PR+, Her2+ |
ZR-75 | Luminal B | ER+, PR-, Her2+ |
SKBR3 | Her2-positive | ER-, PR-, Her2+ |
MDA-MB-453 | Her2-positive | ER-, PR-, Her2+ |
MDA-MB-468 | Basal | ER-, PR-, Her2- |
SUM190 | Basal | ER-, PR-, Her2+ |
BT-20 | Basal | ER-, PR-, Her2- |
MDA-MB-231 | Claudin-low | ER-, PR-, Her2- |
HS-578T | Claudin-low | ER-, PR-, Her2- |
Cal-51 | Claudin-low | ER-, PR-, Her2- |
Name | Site of origin | Hormonal status | PSA expression |
PC-3 | Bone | AR- | No |
DU-145 | Brain | AR- | No |
LNCaP | Lymph node | AS | Yes |
C4-2B | Subline of LNCaP | AI | Yes |
VCaP | Bone | AS | Yes |
CWR22 | Prostate | AS | Yes |
22Rv1 | Subline of 22Rv1 | AI | Yes |
PC-346 | Prostate | AS | Yes |
Type | Relevant ME | Metastases | Costs | Ease | Ref. |
Subcutaneous | No | No | Low | Easy | [51] |
Orthotopic BrCa | Yes | Yes | Low | Easy | [45] |
Orthotopic PCa | Yes | Yes | Medium | Difficult | [55] |
Intratibial | Yes | Yes | Medium | Difficult | [56] |
Intravenous/cardiac | Yes | Yes | Medium | Medium | [60] |
Humanized | Yes | Yes | High | Difficult | [67] |
PDX | Yes | No | High | Difficult | [94] |
- Citation: Valta M, Fagerlund K, Suominen M, Halleen J, Tuomela J. Importance of microenvironment in preclinical models of breast and prostate cancer. World J Pharmacol 2015; 4(1): 47-57
- URL: https://www.wjgnet.com/2220-3192/full/v4/i1/47.htm
- DOI: https://dx.doi.org/10.5497/wjp.v4.i1.47